1. Home
  2. CIFR vs GKOS Comparison

CIFR vs GKOS Comparison

Compare CIFR & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cipher Mining Inc.

CIFR

Cipher Mining Inc.

SELL

Current Price

$6.38

Market Cap

9.0B

Sector

Finance

ML Signal

SELL

Logo Glaukos Corporation

GKOS

Glaukos Corporation

SELL

Current Price

$244.24

Market Cap

9.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CIFR
GKOS
Founded
2021
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
9.7B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
CIFR
GKOS
Price
$6.38
$244.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
22
13
Target Price
$22.86
★ $242.46
AVG Volume (30 Days)
★ 44.8M
1.5M
Earning Date
11-02-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
$223,942,000.00
★ $507,442,000.00
Revenue This Year
N/A
$53.82
Revenue Next Year
$420.16
$28.60
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 48.04
32.33
52 Week Low
$5.07
$87.32
52 Week High
$30.14
$255.19

Technical Indicators

Market Signals
Indicator
CIFR
GKOS
Relative Strength Index (RSI) 34.14 67.59
Support Level $5.07 $143.30
Resistance Level $19.82 $255.19
Average True Range (ATR) 0.84 14.12
MACD 0.26 1.53
Stochastic Oscillator 35.71 87.20

Price Performance

Historical Comparison
CIFR
GKOS

About CIFR Cipher Mining Inc.

Cipher Digital Inc is focused on high-performance computing (HPC) data center development and operations. It is engaged in developing and operating data centers designed for HPC workloads. Its operations include managing power assets and capital allocation in response to market conditions and demand for AI-related computing capacity.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: